<DOC>
	<DOCNO>NCT01526824</DOCNO>
	<brief_summary>In patient suffered ischemic stroke TIA ( mini-stroke ) , well patient candidate neuroendovascular stenting , standard care treat patient antiplatelet therapy , `` blood-thinners '' , common clopidogrel ( Plavix ) without addition aspirin . A relatively common problem encounter patient non-responsiveness clopidogrel therapy . A prior study cardiac patient show addition omega-3 polyunsaturated fatty acid ( Lovaza , `` fish oil '' ) increase patient 's response therapy clopidogrel , study neuro patient . In study , patient divide one two group : study arm , patient receive clopidogrel +/- aspirin well Lovaza . In control arm , patient receive clopidogrel +/- aspirin . Assays do measure responsiveness clopdiogrel day 0 , 12-24 hour load dose , day 3-5 still inpatient , follow-up visit 20-30 day start study . The investigator believe study show increase platelet aggregation patient receive clopidogrel Lovaza .</brief_summary>
	<brief_title>Lovaza 's Effect Clopidogrel Neuro Population</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Gender : Male female Age range : 25 80 year age Study population : Patients require antiplatelet therapy clopidogrel +/ aspirin candidate neuroendovascular stenting ischemic stroke/TIA . Eligible female : Nonpregnant lactating/breastfeeding ; Be surgically sterile least 6 month , postmenopausal , heterosexually active childbearing potential , agree continue use accept method birth control throughout study . Any clinically significant abnormal finding uncovered physical examination and/or clinically significant abnormal laboratory result screen accord clinical judgment Investigators Current alcohol abuse Smokers unable refrain smoke clinical trial Patients already take anticoagulant antiplatelets ( ticlopidine , prasugrel , dipyridamole , cilostazol ) , patient already take PUFAs Patients take medication know interact clopidogrel hold change due increase risk adverse health event . Cytochrome P450 3A4 2C19 ( CYP3A4 , CYP2C19 ) inhibitor substrates know cause competitive inhibition Proton pump inhibitor ( PPIs ) NSAIDs Pregnant woman lactating/breastfeeding woman . Active recent major bleeding ( within 14 day ) use TIMI score ( minor severity acceptable base clinical examination/patient history ) Major severity Intracranial hemorrhage Cardiac tamponade Overt bleeding decrease hemoglobin ≥ 5 g/dl decrease hematocrit ≥ 15 % ( without identifiable site ) Minor severity Spontaneous gross hematuria Spontaneous hematemesis Spontaneous hemoptysis Observed bleeding decrease hemoglobin ≥ 3 g/dl ≤ 5 g/dl ( identifiable site ) History gastric duodenal ulcer Platelet count &lt; 100 x 109/L Serum creatinine &gt; 2 mg/dL Liver injury ( alanine transaminase level &gt; 1.5 time upper limit normal ) Recent surgery ( within 14 day study screen ) Known bleed diathesis include limited Hemophilia Von Willebrand disease Leukemia Clotting factor deficiency Uncontrolled hypertension Sustained systolic blood pressure &gt; 185 mmHg , despite treatment Sustained diastolic blood pressure &gt; 110 mmHg , despite treatment Hypersensitivity intolerance clopidogrel , aspirin , PUFAs and/or document fish allergy Patients currently enrol different study take investigational medication 30 day prior start study .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>